

## Drug Monograph

Drug Name: **Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) tablets**  
 Drug Class: **Anti-Infectives: Antiretroviral Therapy (ART)**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.		
<b>Dosage Forms:</b>	Biktarvy is now available in a 300 mg-120 mg-15 mg tablet.		
<b>Manufacturer:</b>	Manufactured by: Gilead Sciences, Inc., Foster City, CA 94404.		
<b>Indications:</b>	Biktarvy is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.		
<b>Costs:</b>	\$3,393.75 per 30 tablets Wholesale Acquisition Cost		
<b>Summary of Findings:</b>	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).		
<b>Status</b>	<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required	
<b>Recommendation:</b>	<input type="checkbox"/> Open Access	<input checked="" type="checkbox"/> Preferred Drug List	
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Reference	
	<input type="checkbox"/> No PA Required	<input checked="" type="checkbox"/> Preferred	

Prepared by: April Ash, PharmD  
 Date: January 6, 2022